Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MC-1019
- Development stage
- Phase 3
- Lead developer
- Medlab Group
- Modality
- Small Molecules
- Administration
- Buccal
01
Overview
MC-1019 is an investigational cannabinoid-based medicine developed by Medlab Clinical Ltd for the treatment of chronic pain. It is formulated as an oro-buccal spray containing a combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). The product utilizes Medlab's proprietary NanoCelle sub-micron nanoparticle delivery platform, which is designed to enhance the absorption of active ingredients through the buccal mucosa. MC-1019 acts on the endocannabinoid system by targeting CB1 and CB2 receptors to modulate pain signaling. It has been evaluated in prospective observational studies in Australia to assess its safety, tolerability, and efficacy in patients with chronic pain.
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on MC-1019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MC-1019.